Stockscreener 앱 받기
10.38
7.23%
0.70
시간 외 거래:
10.30
-0.08
-0.77%
전일 마감가:
$9.68
열려 있는:
$9.7
하루 거래량:
4.65M
Relative Volume:
1.14
시가총액:
$2.70B
수익:
$6.29B
순이익/손실:
$750.00M
주가수익비율:
3.6042
EPS:
2.88
순현금흐름:
$586.00M
1주 성능:
+10.19%
1개월 성능:
+23.57%
6개월 성능:
-28.17%
1년 성능:
-51.40%
1일 변동 폭
$9.67
$10.42
1주일 범위
$9.155
$10.42
52주 변동 폭
$8.01
$21.25
오가논 & Co Stock (OGN) Company Profile
명칭
Organon Co
전화
551-430-6000
주소
30 HUDSON STREET, JERSEY CITY
OGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
10.38 | 2.52B | 6.29B | 750.00M | 586.00M | 2.88 |
|
LLY
Lilly Eli Co
|
727.21 | 665.99B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.43 | 430.51B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
212.56 | 376.28B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
129.73 | 248.60B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.71 | 209.94B | 63.43B | 16.42B | 14.72B | 6.49 |
오가논 & Co Stock (OGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-09-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-11-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-09-21 | 개시 | Barclays | Overweight |
| 2023-03-16 | 개시 | Raymond James | Outperform |
| 2022-10-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 개시 | Piper Sandler | Neutral |
| 2021-09-01 | 개시 | BofA Securities | Buy |
| 2021-07-22 | 개시 | Citigroup | Buy |
| 2021-06-15 | 개시 | JP Morgan | Neutral |
| 2021-06-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 개시 | Evercore ISI | Outperform |
모두보기
오가논 & Co 주식(OGN)의 최신 뉴스
Co. stock movementJuly 2025 Rallies & Stepwise Entry/Exit Trade Alerts - Newser
Organon & Co. shares rise 3.45% intraday after HKEX censures Henlius Biotech, rebukes former CEO. - AInvest
Organon And Henlius Are Latest To Receive Denosumab Nod In US - insights.citeline.com
Organon and Henlius get FDA nod for Amgen biosimilars - MSN
Organon and Henlius get FDA nod for Amgen biosimilars (OGN) - Seeking Alpha
US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Yahoo Finance
US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Placera.se
Major Breakthrough: FDA Approves Two New Biosimilars to Treat Millions with Bone Health Conditions - Stock Titan
A | What is the PEG ratio of Organon & Co.Quarterly Market Summary & Free Weekly Chart Analysis and Trade Guides - خودرو بانک
Organon's Upside Potential: Can Biosimilars and Women’s Health Drive a Re-rating? - AInvest
Will Raised Revenue Guidance and New Launches Shift Organon's (OGN) Growth Outlook? - simplywall.st
How Investors Are Reacting To Organon (OGN) Lifting 2025 Guidance and CEO Share Purchase - Yahoo Finance
Organon & Co. (OGN) Advances VTAMA Cream, Strengthens Women’s Health Portfolio - MSN
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - MSN
Organon & Co. shares rise 1.57% intraday after Trane Technologies launches Season 5 of Healthy Spaces podcast. - AInvest
Organon & Co. shares fall 1.02% intraday after Genentech files BPCIA complaint against Organon and Henlius. - AInvest
Henlius And Organon Sued In US Over Plans To Market Perjeta Biosimilar - insights.citeline.com
Does Organon's Raised 2025 Guidance Signal a Turning Point for OGN Investors? - simplywall.st
Kahn Brothers' Q2 2025 13F Filing: Alphabet, Comcast, and Organon Highlights - AInvest
Organon in charts: Women's Health revenue up ~3% Y/Y in Q2 - MSN
Roche Sues Organon in First Case Over Biosimilar Copy of Perjeta - Bloomberg Law News
There May Be Some Bright Spots In Organon's (NYSE:OGN) Earnings - Yahoo Finance
Organon & Co. (OGN) Stock Price, News & Analysis - MarketBeat
Daré Bioscience Posts Narrower Q2 Loss - The Motley Fool
OGN’s Market Whiplash: -52.64% YTD Decline, -4.30% Plunge in 30 Days - investchronicle.com
Bullish Organon Insiders Loaded Up On US$651.6k Of Stock - 富途牛牛
Organon & Co.'s Q2 2025 Earnings Call: Unraveling Key Contradictions in Capital Allocation, Nexplanon Growth, and Financial Forecasts - AInvest
LPL Financial LLC Has $4.87 Million Holdings in Organon & Co. (NYSE:OGN) - Defense World
NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation - The Malaysian Reserve
Ex-Dividend Reminder: Cencora, Organon and Esquire Financial Holdings - Nasdaq
5 Must-Read Analyst Questions From Organon’s Q2 Earnings Call - Yahoo Finance
OGN Q2 Deep Dive: Flat Sales, Margin Pressure, and Strategic Shifts Highlight Quarter - Yahoo Finance
Organon's Valuation: Discounted Due to Structural Challenges - AInvest
Organon: Valuation Discount Offset By Structural Headwinds (NYSE:OGN) - Seeking Alpha
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - MSN
Natixis Advisors LLC Has $778,000 Holdings in Organon & Co. (NYSE:OGN) - Defense World
Organon & Co. (OGN): Assessing Dividend Sustainability and Valuation Amid Earnings Pressures and Strategic Catalysts - AInvest
Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend - uk.finance.yahoo.com
Organon & Co. (OGN) Reports Q2 2025 Results - MSN
Organon Q2 Preview: What to expect? - MSN
Organon & Co. (NYSE:OGN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Organon & Co. Reports Q2 2025 Earnings, Raises Full-Year Guidance - AInvest
Organon & Co. (NYSE:OGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Organon & Co. Reports Q2 2025 Financial Results - The Globe and Mail
Organon & Co. Earnings Call: Resilience Amid Challenges - The Globe and Mail
Organon (OGN) Fiscal Q2 Revenue Beats 1% - AOL.com
Organon & Co. (OGN) Slashes 13.13% on Disappointing Earnings - MSN
Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade) (NYSE:OGN) - Seeking Alpha
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Organon & Co. SEC 10-Q Report - TradingView
오가논 & Co (OGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.58%
1.62%
자본화:
|
볼륨(24시간):